Scholarlink

Purpose of Review <p>ChemoBodies, also known as Antibody Drug Conjugate (ADCs), are one of the fastest growing classes of biopharmaceuticals with great therapeutic potential in solid and hematological tumors, with 14 US-FDA products till July 2025, and hundreds are in clinical trials. The purpose of this review is to map each component of ChemoBodies, like antibodies and their novel engineered fragments, next-generation Chemo therapeutic drugs (Payloads), Linkers, and unique conjugation Chemistry used to develop ChemoBodies.</p> Recent Findings <p>After analyzing the components of approved ChemoBodies, the antibodies are mainly used to target hematological tumors (CD33, CD22, CD19, CD79b, BCMA, CD30), and solid tumors (HER2, TROP2, Tissue Factor, Folate receptor Alpha, and c-Met). Which is commonly conjugated via succinimide and maleimide chemistry to DNA-damaging agents (SG3199, Calicheamicin), Microtubule inhibitors (DM1, DM4, MMAE, MMAF), and Topoisomerases I inhibitors (DxD, SN-38). Current advancements in antibody engineering, conjugation chemistry, and novel payloads hope to overcome the challenges associated with current ChemoBodies.</p> Summary <p>ChemoBody, also known as Antibody-Drug Conjugate, represents one of the promising classes of therapeutics in the treatment of Solid and haematological cancers. In this review, we summarized all the technologies employed in the development of the US-FDA-approved and under clinical trial ChemoBody molecules.</p> Graphical Abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Chemotherapeutic Drug—Antibody Conjugates (ChemoBodies): Recent Advances and Future Directions

  • 期刊论文

  • 发表日期：

    2025年10月22日

查看全文
  • Abhishek K. Tiwatane,
  • Prakash Y. Khandave,
  • Sampada Sharad Kulkarni,
  • Kounosuke Oisaki,
  • Abhay H. Pande

摘要

Purpose of Review

ChemoBodies, also known as Antibody Drug Conjugate (ADCs), are one of the fastest growing classes of biopharmaceuticals with great therapeutic potential in solid and hematological tumors, with 14 US-FDA products till July 2025, and hundreds are in clinical trials. The purpose of this review is to map each component of ChemoBodies, like antibodies and their novel engineered fragments, next-generation Chemo therapeutic drugs (Payloads), Linkers, and unique conjugation Chemistry used to develop ChemoBodies.

Recent Findings

After analyzing the components of approved ChemoBodies, the antibodies are mainly used to target hematological tumors (CD33, CD22, CD19, CD79b, BCMA, CD30), and solid tumors (HER2, TROP2, Tissue Factor, Folate receptor Alpha, and c-Met). Which is commonly conjugated via succinimide and maleimide chemistry to DNA-damaging agents (SG3199, Calicheamicin), Microtubule inhibitors (DM1, DM4, MMAE, MMAF), and Topoisomerases I inhibitors (DxD, SN-38). Current advancements in antibody engineering, conjugation chemistry, and novel payloads hope to overcome the challenges associated with current ChemoBodies.

Summary

ChemoBody, also known as Antibody-Drug Conjugate, represents one of the promising classes of therapeutics in the treatment of Solid and haematological cancers. In this review, we summarized all the technologies employed in the development of the US-FDA-approved and under clinical trial ChemoBody molecules.

Graphical Abstract